Ca-HPP

Henry Rodriguez, NIH/NCI, Bethesda

for Hui Zhang, John Hopkins University, Baltimore
Edouard Nice, Monash University, Australia
Connie Jimenez, VU University Medical Center, Amsterdam
Chris Kinsinger, NIH/NCI, Bethesda

Oct 4, 2018
Ca-HPP History

2012 – established

2018 - outcomes

The cancer proteomic landscape and the HUPO Cancer Proteome Project

Connie R. Jimenez, Hui Zhang, Christopher R. Kinsinger and Edouard C. Nice

Abstract

The Human Cancer Proteome Project (Cancer-HPP) is an international initiative organized by HUPO whose key objective is to decipher the human cancer proteome through a coordinated effort by cancer proteome researchers around the world. The ultimate goal is to map the entire human cancer proteome to disclose tumor biology and drive improved diagnostics, treatment and management of cancer. Here we report the progress in the cancer proteomics field to date, and discuss future proteomic developments that will be needed to optimally delineate cancer phenotypes and advance the molecular characterization of this significant disease that is one of the leading causes of death worldwide.

Keywords: Human Cancer Proteome Project, International cancer proteomics initiatives, Clinical tumor proteomics
12 countries from 31 institutions

13 cancer types selected

ICPC
INTERNATIONAL CANCER PROTEOGENOME CONSORTIUM
ICPC Lessons Learned

Defined goal
• develop a cancer atlas that is representative of the diversity of people with their cancers around the world. *involving proteogenomic comprehensive approaches*

Implementation approach
• Coalesce research teams around the world with competency and interest in [clinical] proteogenomics science [CPTAC-like]
• Share SOPs, standards
• Data (DNA, RNA, protein, imaging) – publicly accessible
ICPC possible because of Cancer Moonshot and CPTAC

ICPC [and APOLLO] builds off (does not reinvent) existing program (CPTAC)

CPTAC grounded in rigor & reproducibility

Standards & calibrants

- Global round-robin study – SOPs, NCI-8 spike-in (today, PDX, NCI-7 mix)
- Targeted round-robin study…domestic and international (today, Fit-for-Purpose Targeted Assay Guidelines [Tiers – AACC, FDA, CDC, LabCorp, Quest, ARUP, NEP, Pharma, Academia……MCP journal and ICPC members)
Industry adoption and paving path towards regulatory approval

- Assays validated according to CPTAC guidelines and available for viewing on the CPTAC Assay Portal

**Paving a Path Towards Regulatory Approval**

**2016: FDA working group**

**2018: Ongoing**

- CLSI document C64-A approved
- CPTAC on writing group
Industry examples, such as shown this week @HUPO

HeLa round-robin study
SureQuant Targeted Proteomic Assay (IP-MS → SRM)
Opportunity for Ca-HPP to serve as a vehicle for industry to pilot products (ultimate proteomics focus group)?
- Must be mutually beneficial to both parties (industry *and* academia)

Long-term goal [pan-cancer studies]
- Standards (common analytical reference material (high priority), targeted proteomics panels (which adhere to widely-adopted analytical metrics), etc.....